Shanghai Haohai Biological Technology 過去の業績
過去 基準チェック /56
Shanghai Haohai Biological Technology has been growing earnings at an average annual rate of 5.3%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 15.8% per year. Shanghai Haohai Biological Technology's return on equity is 6.7%, and it has net margins of 15.7%.
主要情報
5.3%
収益成長率
7.0%
EPS成長率
| Biotechs 業界の成長 | 11.0% |
| 収益成長率 | 15.8% |
| 株主資本利益率 | 6.7% |
| ネット・マージン | 15.7% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
収支内訳
Shanghai Haohai Biological Technology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 2,747 | 430 | 1,200 | 254 |
| 30 Jun 24 | 2,746 | 446 | 1,210 | 244 |
| 31 Mar 24 | 2,689 | 432 | 1,209 | 231 |
| 31 Dec 23 | 2,654 | 416 | 1,223 | 220 |
| 30 Sep 23 | 2,530 | 346 | 1,197 | 215 |
| 30 Jun 23 | 2,487 | 315 | 1,179 | 207 |
| 31 Mar 23 | 2,263 | 226 | 1,120 | 197 |
| 31 Dec 22 | 2,130 | 180 | 1,088 | 182 |
| 30 Sep 22 | 2,063 | 203 | 1,132 | 175 |
| 30 Jun 22 | 1,861 | 192 | 1,065 | 171 |
| 31 Mar 22 | 1,805 | 272 | 982 | 169 |
| 31 Dec 21 | 1,750 | 352 | 898 | 168 |
| 30 Sep 21 | 1,702 | 428 | 759 | 156 |
| 30 Jun 21 | 1,674 | 434 | 733 | 143 |
| 31 Mar 21 | 1,594 | 370 | 793 | 135 |
| 31 Dec 20 | 1,324 | 230 | 772 | 126 |
| 30 Sep 20 | 1,343 | 232 | 854 | 121 |
| 30 Jun 20 | 1,306 | 216 | 859 | 121 |
| 31 Mar 20 | 1,437 | 279 | 831 | 120 |
| 31 Dec 19 | 1,595 | 371 | 813 | 116 |
| 30 Sep 19 | 1,537 | 353 | 759 | 108 |
| 30 Jun 19 | 1,570 | 386 | 732 | 108 |
| 31 Mar 19 | 1,478 | 375 | 699 | 100 |
| 31 Dec 18 | 1,546 | 415 | 737 | 95 |
| 30 Sep 18 | 1,523 | 411 | 715 | 89 |
| 30 Jun 18 | 1,501 | 408 | 692 | 83 |
| 31 Mar 18 | 1,423 | 390 | 650 | 80 |
| 31 Dec 17 | 1,345 | 372 | 609 | 76 |
| 30 Sep 17 | 1,214 | 351 | 555 | 67 |
| 30 Jun 17 | 1,083 | 329 | 502 | 59 |
| 31 Mar 17 | 967 | 317 | 440 | 53 |
| 31 Dec 16 | 851 | 305 | 378 | 47 |
| 30 Sep 16 | 787 | 295 | 358 | 44 |
| 30 Jun 16 | 724 | 284 | 337 | 40 |
| 31 Mar 16 | 694 | 279 | 319 | 38 |
| 31 Dec 15 | 664 | 273 | 301 | 35 |
| 30 Sep 15 | 630 | 258 | 278 | 32 |
| 30 Jun 15 | 597 | 243 | 255 | 28 |
| 31 Mar 15 | 556 | 213 | 246 | 27 |
| 31 Dec 14 | 516 | 184 | 236 | 26 |
| 30 Sep 14 | 482 | 169 | 221 | 27 |
| 30 Jun 14 | 449 | 154 | 206 | 28 |
| 31 Mar 14 | 425 | 148 | 192 | 26 |
| 31 Dec 13 | 401 | 142 | 178 | 24 |
質の高い収益: 6826 has high quality earnings.
利益率の向上: 6826's current net profit margins (15.7%) are higher than last year (13.7%).
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 6826's earnings have grown by 5.3% per year over the past 5 years.
成長の加速: 6826's earnings growth over the past year (24.5%) exceeds its 5-year average (5.3% per year).
収益対業界: 6826 earnings growth over the past year (24.5%) exceeded the Biotechs industry 5.5%.
株主資本利益率
高いROE: 6826's Return on Equity (6.7%) is considered low.